Cardiovascular Research

Beyond Reperfusion: Acute Ventricular Unloading and Cardioprotection During Myocardial Infarction.

Authors: Jerry Curran|||Daniel Burkhoff|||Robert A Kloner

Affiliations: + Expand

Abstract

Heart failure is a major cause of morbidity and mortality around the world, and myocardial infarction is its leading cause. Myocardial infarction destroys viable myocardium, and this dead tissue is replaced by a non-contractile scar that results in impaired cardiac function and a significantly increased likelihood of the patient developing heart failure. Limiting infarct scar size has been the target of pre-clinical and clinical investigations for decades. However, beyond reperfusion, few therapies have translated into the clinic that limit its formation. New approaches are needed. This review will focus on new clinical and pre-clinical data demonstrating that acute ventricular unloading prior to reperfusion by means of percutaneous left ventricular support devices reduces ischemia-reperfusion injury and limits infarct scar size. Emphasis will be given to summarizing our current mechanistic understanding of this new therapeutic approach to treating myocardial infarction.

---

Reference List

Go AS, Mozaffarian D, et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410.|||Gheorghiade M, Sopko G, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202–1213.|||Mozaffarian, D., Benjamin, E. J., et al. (2015). Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation, 131, e29–e322.|||Cung TT, Morel O, et al. Cyclosporine before PCI in patients with acute myocardial infarction. The New England Journal of Medicine. 2015;373:1021–1031.|||Ezekowitz JA, Kaul P, et al. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. Journal of the American College of Cardiology. 2009;53:13–20.|||Callender T, Woodward M, et al. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Medicine. 2014;11:e1001699.|||El Aidi H, Adams A, et al. Cardiac magnetic resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial infarction or suspected or known coronary artery disease: a systematic review of prognostic studies. Journal of the American College of Cardiology. 2014;63:1031–1045.|||Burns RJ, Gibbons RJ, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. Journal of the American College of Cardiology. 2002;39:30–36.|||Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. The American Journal of Cardiology. 2005;96:10L–18L.|||Stone GW, Selker HP, et al. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. Journal of the American College of Cardiology. 2016;67:1674–1683.|||Nallamothu BK, Krumholz HM, et al. Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) alliance. The American Journal of Cardiology. 2009;103:1051–1055.|||Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. The American Journal of Medicine. 2001;110:165–174.|||Menees DS, Peterson ED, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. The New England Journal of Medicine. 2013;369:901–909.|||Staat P, Rioufol G, et al. Postconditioning the human heart. Circulation. 2005;112:2143–2148.|||Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet. 2006;367:456–458.|||Lonborg J, Kelbaek H, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circulation. Cardiovascular Interventions. 2010;3:34–41.|||Thibault H, Piot C, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037–1044.|||Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. The New England Journal of Medicine. 2007;357:1121–1135.|||Dirksen MT, Laarman GJ, et al. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovascular Research. 2007;74:343–355.|||Ibanez B, Heusch G, et al. Evolving therapies for myocardial ischemia/reperfusion injury. Journal of the American College of Cardiology. 2015;65:1454–1471.|||Kaski JC, Hausenloy DJ, Gersh BJ, Yellon DM. Managment of myocardial reperfusion injury. London: Springer-Verlag; 2012.|||Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. The Journal of Clinical Investigation. 2013;123:92–100.|||Bulluck, H., Yellon, D. M., et al. (2015). Reducing myocardial infarct size: challenges and future opportunities. Heart.|||Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. Journal of the American College of Cardiology. 2012;59:969–978.|||Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circulation Research. 2013;113:451–463.|||Kloner RA, Hale SL, et al. Cardioprotection: where to from here? Cardiovascular Drugs and Therapy. 2017;31:53–61.|||Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. British Journal of Pharmacology. 2015;172:1913–1932.|||Iliodromitis EK, Cohen MV, et al. What is wrong with cardiac conditioning? We may be shooting at moving targets. Journal of Cardiovascular Pharmacology and Therapeutics. 2015;20:357–369.|||Ye Y, Birnbaum GD, et al. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:1805–1814.|||Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovascular Research. 1998;37:279–289.|||Tan FL, Moravec CS, et al. The gene expression fingerprint of human heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:11387–11392.|||Luo M, Anderson ME. Mechanisms of altered Ca(2)(+) handling in heart failure. Circulation Research. 2013;113:690–708.|||Esposito ML, Zhang Y, et al. Left ventricular unloading before reperfusion promotes functional recovery after acute myocardial infarction. Journal of the American College of Cardiology. 2018;72:501–514.|||Shi H, Zhang G, et al. Studying dynamic features in myocardial infarction progression by integrating miRNA-transcription factor co-regulatory networks and time-series RNA expression data from peripheral blood mononuclear cells. PLoS One. 2016;11:e0158638.|||Burkhoff D, Sayer G, et al. Hemodynamics of mechanical circulatory support. Journal of the American College of Cardiology. 2015;66:2663–2674.|||Uriel N, Sayer G, et al. Mechanical unloading in heart failure. Journal of the American College of Cardiology. 2018;72:569–580.|||Laks H, Ott RA, et al. The effect of left atrial-to-aortic assistance on infarct size. Circulation. 1977;56:II38–II43.|||Laschinger JC, Grossi EA, et al. Adjunctive left ventricular unloading during myocardial reperfusion plays a major role in minimizing myocardial infarct size. The Journal of Thoracic and Cardiovascular Surgery. 1985;90:80–85.|||Smalling RW, Cassidy DB, et al. Improved regional myocardial blood flow, left ventricular unloading, and infarct salvage using an axial-flow, transvalvular left ventricular assist device. A comparison with intra-aortic balloon counterpulsation and reperfusion alone in a canine infarction model. Circulation. 1992;85:1152–1159.|||Van Winkle DM, Matsuki T, et al. Left ventricular unloading during reperfusion does not limit myocardial infarct size. Circulation. 1990;81:1374–1379.|||de Souza CF, de Souza Brito F, et al. Percutaneous mechanical assistance for the failing heart. Journal of Interventional Cardiology. 2010;23:195–202.|||Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. Circulation. 2011;123:533–543.|||Burkhoff D, Naidu SS. The science behind percutaneous hemodynamic support: a review and comparison of support strategies. Catheterization and Cardiovascular Interventions. 2012;80:816–829.|||Kawashima D, Gojo S, et al. Left ventricular mechanical support with Impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO Journal. 2011;57:169–176.|||Kotani Y, Chetan D, et al. Left atrial decompression during venoarterial extracorporeal membrane oxygenation for left ventricular failure in children: current strategy and clinical outcomes. Artificial Organs. 2013;37:29–36.|||Patel, S. M., Lipinski, J., et al. (2018). Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with Impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J.|||Kapur NK, Paruchuri V, et al. Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation. 2013;128:328–336.|||Kapur NK, Paruchuri V, et al. Hemodynamic effects of left atrial or left ventricular cannulation for acute circulatory support in a bovine model of left heart injury. ASAIO Journal. 2015;61:301–306.|||O'Neill WW, Kleiman NS, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126:1717–1727.|||Hira RS, Thamwiwat A, et al. TandemHeart placement for cardiogenic shock in acute severe mitral regurgitation and right ventricular failure. Catheterization and Cardiovascular Interventions. 2014;83:319–322.|||Werdan K, Gielen S, et al. Mechanical circulatory support in cardiogenic shock. European Heart Journal. 2014;35:156–167.|||Muller KD, Sass S, et al. Effect of myocardial oxygen consumption on infarct size in experimental coronary artery occlusion. Basic Research in Cardiology. 1982;77:170–181.|||Baan J, van der Velde ET, et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation. 1984;70:812–823.|||Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. The American Journal of Physiology. 1979;236:H498–H505.|||Burkhoff, D., & Dickstein, M. L. (2015). HARVI-Student: introduction to cardiac mechanics and hemodynamics. Version 1.0.2 Ed., https:itunes.apple.com/us/app/harvi-student/id925278806?mt=8.|||Elkayam U, Tasissa G, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. American Heart Journal. 2007;153:98–104.|||Bayram M, De Luca L, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. The American Journal of Cardiology. 2005;96:47G–58G.|||Follath F, Cleland JG, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202.|||Mebazaa A, Nieminen MS, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. Jama. 2007;297:1883–1891.|||O’Gara PT, Kushner FG, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:e362–e425.|||Kanter J, DeBlieux P. Pressors and inotropes. Emergency Medicine Clinics of North America. 2014;32:823–834.|||Russell JA. Bench-to-bedside review: vasopressin in the management of septic shock. Critical Care. 2011;15:226.|||Thiele H, Zeymer U, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. The New England Journal of Medicine. 2012;367:1287–1296.|||Sun X, Li J, et al. Early assistance with left ventricular assist device limits left ventricular remodeling after acute myocardial infarction in a swine model. Artificial Organs. 2016;40:243–251.|||Meyns B, Stolinski J, et al. Left ventricular support by Catheter-Mountedaxial flow pump reduces infarct size. Journal of the American College of Cardiology. 2003;41:1087–1095.|||Wei X, Li T, et al. Short-term mechanical unloading with left ventricular assist devices after acute myocardial infarction conserves calcium cycling and improves heart function. JACC. Cardiovascular Interventions. 2013;6:406–415.|||Sunagawa, G., Saku, K., et al. (2018). Mechano-chronotropic unloading during the acute phase of myocardial infarction markedly reduces infarct size via the suppression of myocardial oxygen consumption. Journal of Cardiovascular Translational Research.|||Piper HM, Garcia-Dorado D, et al. A fresh look at reperfusion injury. Cardiovascular Research. 1998;38:291–300.|||Bulluck H, Yellon DM, et al. Reducing myocardial infarct size: challenges and future opportunities. Heart. 2016;102:341–348.|||Kapur NK, Qiao X, et al. Mechanical pre-conditioning with acute circulatory support before reperfusion limits infarct size in acute myocardial infarction. JACC. Heart Failure. 2015;3:873–882.|||Hu X, Dai S, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation. 2007;116:654–663.|||Haider H, Jiang S, et al. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circulation Research. 2008;103:1300–1308.|||Watanabe, S., Fish, K., et al. (2018). Left ventricular unloading using an Impella CP improves coronary flow and infarct zone perfusion in ischemic heart failure. Journal of the American Heart Association, 7.|||Remmelink M, Sjauw KD, et al. Acute left ventricular dynamic effects of primary percutaneous coronary intervention from occlusion to reperfusion. Journal of the American College of Cardiology. 2009;53:1498–1502.|||Saku K, Kakino T, et al. Left ventricular mechanical unloading by total support of Impella in myocardial infarction reduces infarct size, preserves left ventricular function, and prevents subsequent heart failure in dogs. Circulation. Heart Failure. 2018;11:e004397.|||Factor SM, Flomenbaum M, et al. The effects of acutely increased ventricular cavity pressure on intrinsic myocardial connective tissue. Journal of the American College of Cardiology. 1988;12:1582–1589.|||Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. The American Journal of Cardiology. 1978;41:1127–1132.|||Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–1172.|||Weisman HF, Bush DE, et al. Cellular mechanisms of myocardial infarct expansion. Circulation. 1988;78:186–201.|||Boyle MP, Weisman HF. Limitation of infarct expansion and ventricular remodeling by late reperfusion. Study of time course and mechanism in a rat model. Circulation. 1993;88:2872–2883.|||Olivetti G, Capasso JM, et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circulation Research. 1990;67:23–34.|||Page-McCaw A, Ewald AJ, et al. Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews. Molecular Cell Biology. 2007;8:221–233.|||Phatharajaree W, Phrommintikul A, et al. Matrix metalloproteinases and myocardial infarction. The Canadian Journal of Cardiology. 2007;23:727–733.|||Suga H, Hayashi T, et al. Regression of cardiac oxygen consumption on ventricular pressure-volume area in dog. The American Journal of Physiology. 1981;240:H320–H325.|||Takaoka H, Takeuchi M, et al. Assessment of myocardial oxygen consumption (Vo2) and systolic pressure-volume area (PVA) in human hearts. European Heart Journal. 1992;13(Suppl E):85–90.|||Clerfond G, Biere L, et al. End-systolic wall stress predicts post-discharge heart failure after acute myocardial infarction. Archives of Cardiovascular Diseases. 2015;108:310–320.|||Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. Journal of Molecular and Cellular Cardiology. 1984;16:497–518.|||Verma, S., Burkhoff, D., et al. (2016). Avoiding hemodynamic collapse during high-risk percutaneous coronary intervention: advanced hemodynamics of impella support. Catheterization and Cardiovascular Interventions.|||Mathuria N, Wu G, et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology. 2017;48:27–34.|||Abuissa H, Roshan J, et al. Use of the Impella microaxial blood pump for ablation of hemodynamically unstable ventricular tachycardia. Journal of Cardiovascular Electrophysiology. 2010;21:458–461.|||Cheung AW, White CW, et al. Short-term mechanical circulatory support for recovery from acute right ventricular failure: clinical outcomes. The Journal of Heart and Lung Transplantation. 2014;33:794–799.|||Derwall M, Brucken A, et al. Doubling survival and improving clinical outcomes using a left ventricular assist device instead of chest compressions for resuscitation after prolonged cardiac arrest: a large animal study. Critical Care. 2015;19:123.|||Ishikawa K, Watanabe S, Lee P, Akar FG, Lee A, Bikou O, Fish K, Kho C, Hajjar RJ. Acute left ventricular unloading reduces atrial stretch and inhibits atrial arrhythmias. Journal of the American College of Cardiology. 2018;72:738–750.|||Krug A, Du Mesnil de R, et al. Blood supply of the myocardium after temporary coronary occlusion. Circulation Research. 1966;19:57–62.|||Kloner RA, Ganote CE, et al. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. The Journal of Clinical Investigation. 1974;54:1496–1508.|||Kloner, R. A., King, K. S., et al. (2018). No-reflow phenomenon in heart and brain. American Journal of Physiology. Heart and Circulatory Physiology.|||Kloner RA, Dai W, et al. No-reflow phenomenon. A new target for therapy of acute myocardial infarction independent of myocardial infarct size. Journal of Cardiovascular Pharmacology and Therapeutics. 2018;23:273–276.|||Delepine S, Furber AP, et al. 3-D MRI assessment of regional left ventricular systolic wall stress in patients with reperfused MI. American Journal of Physiology. Heart and Circulatory Physiology. 2003;284:H1190–H1197.|||Remmelink M, Sjauw KD, et al. Effects of mechanical left ventricular unloading by Impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients. Catheterization and Cardiovascular Interventions. 2010;75:187–194.|||Remmelink M, Sjauw KD, et al. Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheterization and Cardiovascular Interventions. 2007;70:532–537.|||Reinhardt D, Sigusch HH, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002;88:525–530.|||Kloner RA, Bolli R, et al. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation. 1998;97:1848–1867.|||Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66:1146–1149.|||Bolli R. Myocardial ‘stunning’ in man. Circulation. 1992;86:1671–1691.|||Birnbaum Y, Kloner RA. Therapy for myocardial stunning. Basic Research in Cardiology. 1995;90:291–293.|||Przyklenk K, Ghafari GB, et al. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium. Journal of the American College of Cardiology. 1989;13:1176–1183.|||Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. American Heart Journal. 1991;121:1319–1330.|||Sheiban I, Tonni S, et al. Myocardial stunning following coronary angioplasty: Protective effects of calcium-channel blockers. Journal of Cardiovascular Pharmacology. 1992;20(Suppl 5):S18–S24.|||Monnet X, Colin P, et al. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. European Heart Journal. 2004;25:579–586.|||Kurose M, Okamoto K, et al. Emergency and long-term extracorporeal life support following acute myocardial infarction: rescue from severe cardiogenic shock related to stunned myocardium. Clinical Cardiology. 1994;17:552–557.|||Roolvink, V., Ibanez, B., et al. (2016). Early administration of intravenous beta blockers in patients with ST-elevation myocardial infarction before primary PCI. Journal of the American College of Cardiology.|||Arimura T, Saku K, et al. Intravenous electrical vagal nerve stimulation prior to coronary reperfusion in a canine ischemia-reperfusion model markedly reduces infarct size and prevents subsequent heart failure. International Journal of Cardiology. 2017;227:704–710.|||Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction (www.clinicaltrials.gov, NCT03000270).|||Kapur, N. K., Alkhouli, M., DeMartini, T., Faraz, H., George, Z., Goodwin, M., Hernandez-Montfort, J. A., Iyer, V., Josephy, N., Sanjog, K., Kaki, A., Karas, R. H., & Kimmelstiel, C. (2018). Unloading the left ventricle before reperfusion in patients with anterior ST-segment elevation myocardial infarction: a pilot study using the Impella CP (In Press). Circulation.